Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

CONVERGE Post-Approval Study (PAS)

NCT05393180 · View on ClinicalTrials.gov ↗

Study Summary

The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.

Interventions

  • DEVICE Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF

Study Locations (13)

Florida

  • Baycare Health Systems — Clearwater
  • Orlando Health — Orlando

Georgia

  • Emory Saint Joseph Hopsital — Atlanta
  • Wellstar Health System — Marietta

California

  • Sutter Bay Hospitals — San Francisco

Connecticut

  • Hartford Hospital — Hartford

Kentucky

  • Norton Heart & Vascular Institute — Louisville

Maryland

  • MedStar Union Memorial Hospital — Baltimore

Massachusetts

  • Southcoast Hospitals Group — New Bedford

New Jersey

  • AtlantiCare Medical Center — Atlantic City

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2022-04-13
Est. Completion 2029-01-01
Phase NA

Sponsor

AtriCure

13 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05393180

The ClinicalTrials.gov registry entry for NCT05393180 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AtriCure, which has 13 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Chronic Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention — of which Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05393180 reports 13 study locations spanning 11 distinct geographic areas — top geographies include Florida, Georgia, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05393180 about?

NCT05393180 is a clinical study titled "CONVERGE Post-Approval Study (PAS)". The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillati...

What is the current status of trial NCT05393180?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 53 participants. The study started on 2022-04-13. Estimated completion is 2029-01-01.

What conditions does trial NCT05393180 study?

This clinical trial studies the following conditions: Chronic Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05393180?

The interventions under investigation include: Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05393180?

This trial is sponsored by AtriCure, which has 13 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05393180 being conducted?

This trial has 13 study locations across California, Connecticut, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial